MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Type of Assessment:

Air in the Pleural Cavity Enhances Detection of Pleural Abnormalities by CT Scan

Chest 2018 June [Link] Fysh ETH, Thomas R, Tobin C, Kuok YJ, Lee YCG Abstract Detection of pleural abnormalities on CT scan is critical in diagnosis of pleural disease. CT scan detects minute parenchymal lung nodules, but often fails to detect similar-sized pleural nodularity. This is likely because the density of the visceral/parietal pleura and […]

Comments Off on Air in the Pleural Cavity Enhances Detection of Pleural Abnormalities by CT Scan

Peritoneal Metastases from Gastrointestinal Cancer

Current Oncology Reports 2018 June 8 [Link] Sugarbaker PH Abstract PURPOSE OF REVIEW: Peritoneal metastases may occur from a majority of cancers that occur within the abdomen or pelvis. When cancer spread to the peritoneal surfaces is documented, a decision regarding palliation vs. an aggressive approach using cytoreductive surgery (CRS) and perioperative intraperitoneal chemotherapy must […]

Comments Off on Peritoneal Metastases from Gastrointestinal Cancer

Proton beam therapy for malignant pleural mesothelioma.

Translational Lung Cancer Research 2018 April 7 [Link] Badiyan SN, Molitoris JK, Zhu M, Glass E, Diwanji T, Simone CB Abstract Malignant pleural mesothelioma (MPM) is a rare disease with a poor prognosis. Surgical techniques have made incremental improvements over the last few decades while new systemic therapies, including immunotherapies, show promise as potentially effective […]

Comments Off on Proton beam therapy for malignant pleural mesothelioma.

A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol.

Clinical Lung Cancer 2018 May 9 [Link] Fujimoto N, Aoe K, Kozuki T, Oze I, Kato K, Kishimoto T, Hotta K

Comments Off on A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol.

Immunohistochemically detectable metallothionein expression in malignant pleural mesotheliomas is strongly associated with early failure to platin-based chemotherapy.

Oncotarget 2018 April 27 [Link] Mairinger FD, Schmeller J, Borchert S, Wessolly M, Mairinger E, Kollmeier J, Hager T, Mairinger T, Christoph DC, Walter RFH, Eberhardt WEE, Plönes T, Wohlschlaeger J, Jasani B, Schmid KW, Bankfalvi A Abstract BACKGROUND: Malignant pleural mesothelioma (MPM) is a biologically highly aggressive tumor arising from the pleura with a […]

Comments Off on Immunohistochemically detectable metallothionein expression in malignant pleural mesotheliomas is strongly associated with early failure to platin-based chemotherapy.

Cancer incidence in a cohort of asbestos-exposed workers undergoing health surveillance.

International Archives of Occupational and Environmental Health 2018 June 5 [Link] Barbiero F, Zanin T, Pisa FE, Casetta A, Rosolen V, Giangreco M, Negro C, Bovenzi M, Barbone F Abstract OBJECTIVES: To compare a local cohort of 2488 men occupationally exposed to asbestos and enrolled in a public health surveillance program with the 1995-2009 cancer […]

Comments Off on Cancer incidence in a cohort of asbestos-exposed workers undergoing health surveillance.

Soluble CD157 in pleural effusions: a complementary tool for the diagnosis of malignant mesothelioma.

Oncotarget 2018 April 27 [Link] Augeri S, Capano S, Morone S, Fissolo G, Giacomino A, Peola S, Drace Z, Rapa I, Novello S, Volante M, Righi L, Ferrero E, Ortolan E, Funaro A Abstract BACKGROUND: CD157/Bst1 glycoprotein is expressed in >85% of malignant pleural mesotheliomas and is a marker of enhanced tumor aggressiveness. RESULTS: In […]

Comments Off on Soluble CD157 in pleural effusions: a complementary tool for the diagnosis of malignant mesothelioma.

Surgical Options for Malignant Mesothelioma: A Single-Center Experience.

The Korean Journal of Thoracic and Cardiovascular Surgery 2018 June 5 [Link] Kang SR, Bok JS, Lee GD, Choi SH, Kim HR, Kim DK, Park SI, Kim YH Abstract BACKGROUND: We investigated the surgical outcomes of patients who underwent therapeutic surgery for malignant pleural mesothelioma (MPM) at a single center. METHODS: A retrospective review of […]

Comments Off on Surgical Options for Malignant Mesothelioma: A Single-Center Experience.

18F-fluorodeoxyglucose imaging of primary malignant pericardial mesothelioma with concurrent pericardial and pleural effusions and bone metastasis: A case report.

Molecular and Clinical Oncology 2018 June 8 [Link] Li X, Lu R, Zhao Y, Wang F, Shao G Abstract Primary malignant pericardial mesothelioma (PMPM) is an aggressive tumor that originates from the mesothelial cells of the pericardium. PMPM with extensive atrial infiltration and bone metastasis is extremely rare. The diagnosis and staging of PMPM based […]

Comments Off on 18F-fluorodeoxyglucose imaging of primary malignant pericardial mesothelioma with concurrent pericardial and pleural effusions and bone metastasis: A case report.

Recurrence of Pericardial Mesothelioma Affecting the Myocardium after Pericardial Resection.

The Annals of Thoracic Surgery 2018 May 21 [Link] Rodríguez M, Mallidi HR, da Silva A, Bueno R Abstract Primary pericardial mesothelioma represents less than 1% of all malignant mesotheliomas. These tumors are very rare, difficult to diagnose and with poor response to stablished treatments. Common clinical presentations include constrictive symptoms, cardiac tamponade and cardiac […]

Comments Off on Recurrence of Pericardial Mesothelioma Affecting the Myocardium after Pericardial Resection.